0	8	Evidence	evidence	NN
9	12	for	for	IN
13	23	suppressed	suppress	VBN
24	32	activity	activity	NN
33	35	of	of	IN
36	39	the	the	DT
40	53	transcription	transcription	NN
54	60	factor	factor	NN
61	66	NFAT1	nfat1	NN
67	69	at	at	IN
70	73	its	its	PRP$
74	82	proximal	proximal	JJ
83	90	binding	binding	NN
91	98	element	element	NN
99	101	P0	p0	NN
102	104	in	in	IN
105	108	the	the	DT
109	113	IL-4	il-4	NN
114	122	promoter	promoter	NN
123	133	associated	associate	VBN
134	138	with	with	IN
139	147	enhanced	enhance	VBN
148	152	IL-4	il-4	NN
153	157	gene	gene	NN
158	171	transcription	transcription	NN
172	174	in	in	IN
175	176	T	t	NN
177	182	cells	cell	NNS
183	185	of	of	IN
186	192	atopic	atopic	JJ
193	201	patients	patient	NNS
201	202	.	.	.

204	221	Allergen-specific	allergen-specific	JJ
222	223	T	t	NN
224	229	cells	cell	NNS
230	232	in	in	IN
233	239	atopic	atopic	JJ
240	248	patients	patient	NNS
249	252	are	be	VBP
253	262	polarized	polarize	VBN
263	277	IL-4-producing	il-4-producing	JJ
278	281	Th2	th2	NN
282	287	cells	cell	NNS
287	288	,	,	,
289	298	promoting	promote	VBG
299	302	IgE	ige	NN
303	312	synthesis	synthesis	NN
313	315	by	by	IN
316	317	B	B	NNP
318	323	cells	cell	NNS
323	324	.	.	.

325	328	The	the	DT
329	338	molecular	molecular	JJ
339	344	basis	basis	NN
345	348	for	for	IN
349	358	increased	increase	VBN
359	363	IL-4	il-4	NN
364	368	gene	gene	NN
369	379	expression	expression	NN
380	382	in	in	IN
383	388	atopy	atopy	NN
389	391	is	be	VBZ
392	395	not	not	RB
396	401	fully	fully	RB
402	412	understood	understand	VBN
412	413	.	.	.

414	418	IL-4	il-4	NN
419	423	gene	gene	NN
424	434	regulation	regulation	NN
435	437	in	in	IN
438	445	general	general	JJ
446	454	involves	involve	VBZ
455	458	the	the	DT
459	466	nuclear	nuclear	JJ
467	473	factor	factor	NN
474	476	of	of	IN
477	486	activated	activate	VBN
487	488	T	t	NN
489	494	cells	cell	NNS
495	496	(	(	(
496	500	NFAT	NFAT	NNP
500	501	)	)	)
502	508	family	family	NN
509	511	of	of	IN
512	525	transcription	transcription	NN
526	533	factors	factor	NNS
533	534	,	,	,
535	537	of	of	IN
538	543	which	which	WDT
544	549	NFAT1	NFAT1	NNP
550	553	and	and	CC
554	559	NFAT2	NFAT2	NNP
560	563	are	be	VBP
564	568	most	most	RBS
569	578	prominent	prominent	JJ
579	581	in	in	IN
582	592	peripheral	peripheral	JJ
593	594	T	t	NN
595	600	cells	cell	NNS
600	601	.	.	.

602	610	Recently	recently	RB
610	611	,	,	,
612	613	a	a	DT
614	620	unique	unique	JJ
621	631	inhibitory	inhibitory	JJ
632	636	role	role	NN
637	639	of	of	IN
640	645	NFAT1	nfat1	NN
646	648	in	in	IN
649	653	IL-4	il-4	NN
654	658	gene	gene	NN
659	666	control	control	NN
667	670	was	be	VBD
671	676	shown	show	VBN
677	679	in	in	IN
680	683	the	the	DT
684	689	mouse	mouse	NN
689	690	.	.	.

691	693	In	in	IN
694	695	a	a	DT
696	702	series	series	NN
703	705	of	of	IN
706	721	electrophoretic	electrophoretic	JJ
722	730	mobility	mobility	NN
731	736	shift	shift	NN
737	743	assays	assay	NNS
744	748	with	with	IN
749	756	protein	protein	NN
757	765	extracts	extract	NNS
766	768	of	of	IN
769	775	highly	highly	RB
776	785	polarized	polarize	VBN
786	789	Th2	th2	NN
790	796	clones	clone	NNS
797	801	from	from	IN
802	809	atopics	atopic	NNS
810	813	and	and	CC
814	817	Th1	th1	NN
818	824	clones	clone	NNS
825	829	from	from	IN
830	838	controls	control	NNS
839	841	we	we	PRP
842	850	compared	compare	VBD
851	862	DNA-binding	dna-binding	JJ
863	873	activities	activity	NNS
874	876	at	at	IN
877	880	the	the	DT
881	884	two	two	CD
885	897	NFAT-binding	nfat-binding	JJ
898	906	elements	element	NNS
907	909	P0	P0	NNP
910	913	and	and	CC
914	916	P1	p1	NN
917	919	of	of	IN
920	923	the	the	DT
924	931	crucial	crucial	JJ
932	940	proximal	proximal	JJ
941	946	human	human	JJ
947	951	IL-4	il-4	NN
952	960	promoter	promoter	NN
960	961	.	.	.

962	964	At	at	IN
965	968	the	the	DT
969	973	most	most	RBS
974	982	proximal	proximal	JJ
983	985	P0	p0	NN
986	990	site	site	NN
990	991	,	,	,
992	1007	NFAT-containing	nfat-containing	JJ
1008	1017	complexes	complex	NNS
1018	1024	devoid	devoid	JJ
1025	1027	of	of	IN
1028	1033	NFAT2	nfat2	NN
1034	1038	were	be	VBD
1039	1046	readily	readily	RB
1047	1056	inducible	inducible	JJ
1057	1059	in	in	IN
1060	1063	the	the	DT
1064	1067	Th1	th1	NN
1068	1074	clones	clone	NNS
1074	1075	,	,	,
1076	1079	but	but	CC
1080	1086	hardly	hardly	RB
1087	1089	or	or	CC
1090	1093	not	not	RB
1094	1096	in	in	IN
1097	1100	the	the	DT
1101	1104	Th2	th2	NN
1105	1111	clones	clone	NNS
1111	1112	.	.	.

1113	1115	In	in	IN
1116	1124	contrast	contrast	NN
1124	1125	,	,	,
1126	1130	both	both	CC
1131	1133	in	in	IN
1134	1137	Th1	th1	NN
1138	1141	and	and	CC
1142	1145	Th2	th2	NN
1146	1152	clones	clone	NNS
1153	1168	NFAT-containing	nfat-containing	JJ
1169	1178	complexes	complex	NNS
1179	1183	were	be	VBD
1184	1192	strongly	strongly	RB
1193	1202	inducible	inducible	JJ
1203	1205	at	at	IN
1206	1209	the	the	DT
1210	1212	P1	p1	NN
1213	1217	site	site	NN
1217	1218	,	,	,
1219	1229	consisting	consist	VBG
1230	1232	of	of	IN
1233	1238	NFAT2	nfat2	NN
1239	1242	and	and	CC
1243	1244	a	a	DT
1245	1258	P0-compatible	p0-compatible	JJ
1259	1263	NFAT	nfat	NN
1264	1272	activity	activity	NN
1272	1273	,	,	,
1274	1281	without	without	IN
1282	1290	apparent	apparent	JJ
1291	1302	differences	difference	NNS
1303	1310	between	between	IN
1311	1314	Th1	th1	NN
1315	1318	and	and	CC
1319	1322	Th2	th2	NN
1323	1329	clones	clone	NNS
1329	1330	.	.	.

1331	1335	Like	like	IN
1336	1338	in	in	IN
1339	1342	Th2	th2	NN
1343	1349	clones	clone	NNS
1349	1350	,	,	,
1351	1361	suppressed	suppress	VBD
1362	1369	NFAT-P0	NFAT-P0	NNP
1370	1377	complex	complex	NN
1378	1387	formation	formation	NN
1388	1391	was	be	VBD
1392	1400	observed	observe	VBN
1401	1405	also	also	RB
1406	1408	at	at	IN
1409	1412	the	the	DT
1413	1423	polyclonal	polyclonal	JJ
1424	1429	level	level	NN
1430	1432	in	in	IN
1433	1443	peripheral	peripheral	JJ
1444	1449	blood	blood	NN
1450	1461	mononuclear	mononuclear	JJ
1462	1467	cells	cell	NNS
1468	1469	(	(	(
1469	1473	PBMC	PBMC	NNP
1473	1474	)	)	)
1475	1477	of	of	IN
1478	1483	three	three	CD
1484	1486	of	of	IN
1487	1491	five	five	CD
1492	1498	severe	severe	JJ
1499	1505	atopic	atopic	JJ
1506	1516	dermatitis	dermatitis	NN
1517	1525	patients	patient	NNS
1526	1530	with	with	IN
1531	1539	strongly	strongly	RB
1540	1548	elevated	elevated	JJ
1549	1554	serum	serum	NN
1555	1558	IgE	ige	NN
1559	1565	levels	level	NNS
1565	1566	,	,	,
1567	1570	but	but	CC
1571	1574	not	not	RB
1575	1577	in	in	IN
1578	1585	control	control	NN
1586	1590	PBMC	PBMC	NNP
1590	1591	.	.	.

1592	1597	These	these	DT
1598	1606	findings	finding	NNS
1607	1614	suggest	suggest	VBP
1615	1619	that	that	IN
1620	1630	high-level	high-level	JJ
1631	1635	IL-4	il-4	NN
1636	1646	production	production	NN
1647	1649	in	in	IN
1650	1656	atopic	atopic	JJ
1657	1660	Th2	th2	NN
1661	1666	cells	cell	NNS
1667	1669	is	be	VBZ
1670	1680	associated	associate	VBN
1681	1685	with	with	IN
1686	1695	selective	selective	JJ
1696	1705	reduction	reduction	NN
1706	1708	of	of	IN
1709	1720	suppressive	suppressive	JJ
1721	1726	NFAT1	nfat1	NN
1727	1735	activity	activity	NN
1736	1738	at	at	IN
1739	1742	the	the	DT
1743	1747	IL-4	il-4	NN
1748	1750	P0	p0	NN
1751	1758	element	element	NN
1759	1762	and	and	CC
1763	1767	that	that	IN
1768	1772	some	some	DT
1773	1781	patients	patient	NNS
1782	1786	with	with	IN
1787	1791	this	this	DT
1792	1806	multifactorial	multifactorial	JJ
1807	1814	disease	disease	NN
1815	1818	may	may	MD
1819	1823	have	have	VB
1824	1825	a	a	DT
1826	1834	putative	putative	JJ
1835	1843	systemic	systemic	JJ
1844	1852	disorder	disorder	NN
1853	1855	at	at	IN
1856	1860	this	this	DT
1861	1866	level	level	NN
1866	1867	.	.	.